One potential strategy for priming the tumor microenvironment (TME) for immune checkpoint therapy is to induce tumor infiltrating lymphocytes and adaptive immune resistance pathways through the use of therapeutic cancer vaccines.4 The GVAX colon vaccine is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)‐secreting cellular immunotherapy that induces T‐cell immunity against a broad range of colon cancer‐associated antigens. The gene discussed is CSF2; the disease is neoplasm.